CryoLife To Present At U.S. Bancorp Piper Jaffray Health Care Conference In New York

January 28, 2003 at 9:37 AM EST

ATLANTA, Jan. 28 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a human tissue processing and medical device company, today announced that Steven G. Anderson, president and CEO, will present a Company overview at the 15th Annual U.S. Bancorp Piper Jaffray Health Care Conference at the Pierre Hotel in New York City, Thursday, January 30. The CryoLife presentation is scheduled for 2:00 p.m. EST.

A live webcast of the conference will be available at http://www.gotoanalysts.com/hccwebcast . The audio portion of CryoLife's presentation may also be accessed at, www.cryolife.com , on the Investor Relations page. An archived copy of the presentation will be available for 30 days on both Web sites.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in surgeries throughout the United States and Canada. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels and is CE-marked in the European Community and approved in Canada and Australia for use in vascular and pulmonary sealing and repair. The Company also manufactures the SynerGraft(R) vascular graft, the world's first tissue-engineered vascular replacement, which is CE-marked for distribution within the European Community. The human grafts processed by CryoLife using the SynerGraft technology are distributed in the U.S. under the trade names CryoValve(R)SG and CryoVein(R)SG.

For additional information about the company, visit CryoLife's web site: http://www.cryolife.com . SOURCE CryoLife, Inc.

/CONTACT: D. Ashley Lee, Vice President & Chief Financial Officer and Treasurer of CryoLife, +1-770-419-3355; or Katie Brazel of Fleishman Hillard, +1-404-739-0150, for CryoLife/